Providing medicines that matter, it’s what we do
For decades, we’ve been providing patients with a wide range of high quality and trusted specialty medicines.
Leveraging generations of knowledge and expertise, ADVANZ PHARMA is rapidly building a new portfolio of biosimilars, further expanding patient access to biological specialty medicines.
Biosimilars are a vital part of our work
The introduction of biologics in the 1990s transformed patients’ lives in many clinical settings1.
Biosimilars provide clinically proven, cost-effective alternatives to originator products1,2 and make life-changing therapies more accessible for a broader range of patients.
With biologics accounting for over 50% of new medicine approvals2, biosimilars reduce treatment costs, alleviating financial pressure on healthcare systems1,2 and providing the budget headroom for payers to fund important innovation in areas with unmet medical need.
Biosimilars diversify therapeutic portfolios, empowering prescribers with more choices to tailor treatments to individual patient needs without compromising quality or outcomes.
Rigorous regulatory evaluations ensure that biosimilars meet the same high standards of safety, efficacy, and quality as originator biologics, giving prescribers confidence in their clinical use and allowing them to switch patients-on-therapy to biosimilars to lower the cost burden on healthcare systems.
With more than 30 active ingredients that are approved and marketed as biosimilars in Europe to date, biosimilars are an established treatment principle. A further >100 biologics are anticipated to lose patent protection by the end of 20323, bringing a major opportunity for access to modern drugs at an affordable price to more patients.
To ensure greater access to medicines for patients, ADVANZ PHARMA is partnering with leading Biosimilars Development and Manufacturing Organisations and combines their scientific and technological with our commercial expertise.
What matters to you, matters to us
Quality, reliability & trust
Our experience makes us a trusted partner.
With our proven track record navigating the complexities of affordability, access, and supply that challenge stakeholders in the European healthcare system, we are uniquely placed to provide patients with high quality biosimilar therapies.
A legacy in different therapy areas
ADVANZ PHARMA has gained a deep understanding of the specific needs of healthcare professionals.
Decades of expertise
As an established provider of speciality medicines, ADVANZ PHARMA understands the complexities associated with the access and affordability.
Partnering with globally recognised Biosimilars Development and Manufacturing Organisations
ADVANZ PHARMA partners with globally leading Biosimilars Development and Manufacturing Organisations to manufacture products in state-of-the-art facilities that meet strict quality control and high environmental standards, ensuring reliable global supply.
Long-term commitment: a strong and ever-growing pipeline
Carefully selecting biosimilar assets where the original biologic is already placing a substantial cost burden to European healthcare systems.
Targeting high-demand therapy areas such as autoimmune, ophthalmology, and respiratory, with several new products planned for launch in the coming years.
- Golimumab (biosimilar of Simponi®)
- Aflibercept (biosimilar of Eylea®)
- Omalizumab (biosimilar to Xolair®)
- Vedolizumab (biosimilar of Entyvio®)
- Dupilumab (biosimilar of Dupixent®)
- Ixekizumab (biosimilar of Taltz®)
- Guselkumab (biosimilar of Tremfya®)
- Canakinumab (biosimilar of Ilaris®)
- Ofatumumab (biosimilar of Kesimpta®)
- Two undisclosed biosimilars
Meeting patient needs
At ADVANZ PHARMA, we are focused on tailored care, offering a range of presentations, dosages, and delivery systems designed to meet patient needs.
Providing suitable presentations and dosages
We support healthcare professionals in delivering high-quality care with appropriate presentations and dosages.
Providing a range of delivery systems
We aim to give healthcare professionals the confidence to switch patients-on-therapy to biosimilars to lower the cost burden on healthcare systems.
Patient-centred therapy transition
At ADVANZ PHARMA, we partner with healthcare providers and deliver the necessary resources and support programs to make therapy transitions straightforward, integrating biosimilars into everyday clinical practice.
Working closely with prescribers
We address their needs to ensure biosimilar therapies are integrated into clinical practice and deliver tangible benefits to patients.
Collaborating with patient groups
We work with patient groups to understand their needs and clinical pathways and to ensure our solutions bring value to patients.